Ultragenyx Pharmaceutical RARE Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Collaboration And Royalty | $471.14M-2.1% | $481.14M+6.6% | $451.25M+3.2% | $437.15M+1.6% | $430.42M+5.0% | |
| Non Cash Royalty | $112.81M+0.9% | $111.81M+3.7% | $107.83M+1.8% | $105.97M+4.0% | $101.94M+0.9% | |
| Royalty | $303.22M-0.3% | $304.22M+4.3% | $291.81M+0.9% | $289.11M+4.5% | $276.66M+0.6% | |
| Revenue by Geography | ||||||
| Asia Pacific | $18.72M+5.6% | $17.72M+10.8% | $15.99M+21.6% | $13.15M+9.6% | $12M+33.3% | |
| EMEA | $115.67M+7.4% | $107.67M+4.6% | $102.93M+5.8% | $97.27M+11.8% | $87.03M+8.8% | |
| Latin America | $157.11M-7.6% | $170.11M+13.3% | $150.18M+3.7% | $144.86M-4.0% | $150.82M+15.1% | |
| North America | $378.21M+0.3% | $377.21M+4.5% | $360.98M+1.9% | $354.36M+4.1% | $340.32M+0.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ultragenyx Pharmaceutical break its business down?
- Ultragenyx Pharmaceutical (RARE) reports revenue by product across 3 parts — Collaboration And Royalty, Non Cash Royalty and Royalty. Each is extracted from the segment footnotes and tracked over time.
- Where does Ultragenyx Pharmaceutical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ultragenyx Pharmaceutical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.